Saoirse E. O'sullivan

James's Street
Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.

Journal: British journal of clinical pharmacology

Published: March 30, 2026

Evaluating FABP5 as a Therapeutic Target for Pain Management.

Evaluating FABP5 as a Therapeutic Target for Pain Management.

Journal: European journal of pain (London, England)

Published: October 14, 2025

The emerging role of fatty acid-binding protein 3 (FABP3) in cancer.

The emerging role of fatty acid-binding protein 3 (FABP3) in cancer.

Journal: Drug discovery today

Published: September 02, 2025

A novel cannabidiol:tetramethylpyrazine cocrystal (CBD:TMP, ART12.11) improves the efficacy and bioavailability of cannabidiol in reducing stress-induced depressive and anxiety symptoms.

A novel cannabidiol:tetramethylpyrazine cocrystal (CBD:TMP, ART12.11) improves the efficacy and bioavailability of cannabidiol in reducing stress-induced depressive and anxiety symptoms.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: February 20, 2025

ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models.

ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models.

Journal: The Journal of investigative dermatology

Published: October 25, 2024

Potential safety implications of fatty acid-binding protein inhibition.

Potential safety implications of fatty acid-binding protein inhibition.

Journal: Toxicology and applied pharmacology

Published: June 07, 2024

ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models.

ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models.

Journal: European journal of pain (London, England)

Published: May 02, 2024

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.

Journal: Breast cancer research and treatment

Published: February 07, 2024

Strategies to Improve Cannabidiol Bioavailability and Drug Delivery.

Strategies to Improve Cannabidiol Bioavailability and Drug Delivery.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 11, 2024

The emerging role of fatty acid binding protein 7 (FABP7) in cancers.

The emerging role of fatty acid binding protein 7 (FABP7) in cancers.

Journal: Drug discovery today

Published: December 07, 2023

Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration Is Prevented via Cannabinoid Receptor 2 Agonism In Vitro.

Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration Is Prevented via Cannabinoid Receptor 2 Agonism In Vitro.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 13, 2023

Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.

Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.

Journal: The journal of pain

Published: September 21, 2023

Showing 1-12 of 86

Last Updated: 09/26/2026